We are encouraged by the number of patients and families supported by our products and services. It motivates us to continue to seek ways to improve the patient and provider experience with these products and to deliver our therapies to more people who could benefit from them.
In collaboration with research physicians, we are conducting a large clinical trial that will add to the body of knowledge provided by the NICHD MFMU Network study of hydroxyprogesterone caproate (HPC) injection (Meis NEJM 2003), now available as FDA-approved Makena. To date, the company has enrolled more than 1,100 participants in the study.1,3
We are also developing a potential subcutaneous autoinjector, which, if successfully developed and approved, could improve the patient and provider experience with our product.